McLean A J, Skews H, Bobik A, Dudley F J
Clin Pharmacol Ther. 1980 Jun;27(6):726-32. doi: 10.1038/clpt.1980.103.
Seven healthy subjects were given oral propranolol (1 mg/kg) alone or in combination with hydralazine 25, 50, or 100 mg on separate occasions. Hydralazine induced variable increases in the peak concentrations (p less than 0.05) and in the area under the propranolol concentration: time curves (p less than 0.02) without change in the recovery of 14 C-propranolol/metabolites in urine or in the systemic clearance of propranolol; i.e., oral hydralazine enhanced the systemic availability of propranolol by alteration of "first-pass" (hepatic) clearance. The results indicate the possibility of change in presystemic clearance without reciprocal change in systemic clearance and also suggest that propranolol or any other high-clearance drug should be administered in fixed relationship to hydralazine and other drugs capable of altering "first-pass" hepatic extraction (either due to alteration in splanchnic blood flow or competitive inhibition of metabolism) if large variations in plasma concentrations are to be avoided.
7名健康受试者分别单独口服普萘洛尔(1毫克/千克),或与25毫克、50毫克或100毫克肼屈嗪联合服用。肼屈嗪使普萘洛尔的峰值浓度(p<0.05)和普萘洛尔浓度-时间曲线下面积(p<0.02)出现不同程度的增加,而尿中14C-普萘洛尔/代谢物的回收率或普萘洛尔的全身清除率未发生变化;也就是说,口服肼屈嗪通过改变“首过”(肝脏)清除率提高了普萘洛尔的全身可用性。结果表明,存在肝前清除率改变而全身清除率无相应改变的可能性,这也提示,如果要避免血浆浓度出现较大波动,普萘洛尔或任何其他高清除率药物与肼屈嗪及其他能够改变肝脏“首过”摄取(无论是由于内脏血流量改变还是代谢的竞争性抑制)的药物合用时,应以固定比例给药。